EGFR and non-small cell lung carcinoma: The IPASS study and the NEJ002 research showed that gefitinib prolongs median progression-free survival (mPFS) and enhances response rate compared with patients with advanced NSCLC with EGFR mutations who received chemotherapy [2, 22].